{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:31:34Z","timestamp":1787581894964,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA257906"],"award-info":[{"award-number":["P01 CA257906"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA223220"],"award-info":[{"award-number":["R01 CA223220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA284386"],"award-info":[{"award-number":["R01 CA284386"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["UG1 CA233259"],"award-info":[{"award-number":["UG1 CA233259"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA217691"],"award-info":[{"award-number":["P50 CA217691"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.218010","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:46:34Z","timestamp":1756482394000},"page":"218010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Targeting MKK3\/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer"],"prefix":"10.1016","volume":"633","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3949-5744","authenticated-orcid":false,"given":"Zhen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Vallega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Bildtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey A.","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-8826","authenticated-orcid":false,"given":"Shi-Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218010_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canlet.2025.218010_bib2","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.canlet.2025.218010_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091515","article-title":"Non-small cell lung cancer with epidermal growth Factor Receptor (EGFR) common mutations: new strategies","volume":"17","author":"Stanzione","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.218010_bib4","first-page":"82","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","author":"Du","year":"2025","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.canlet.2025.218010_bib5","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer","volume":"29","author":"Blaquier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218010_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2025.218010_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050847","article-title":"New treatment strategies in advanced epidermal growth factor receptor-driven non-small cell lung cancer: beyond single agent osimertinib","volume":"17","author":"Maione","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.218010_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218010_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-021-00500-y","article-title":"Alternative approaches to target Myc for cancer treatment","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.218010_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pccm.2023.07.001","article-title":"Role of c-Myc in lung cancer: progress, challenges, and prospects","volume":"1","author":"Wallbillich","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"10.1016\/j.canlet.2025.218010_bib11","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-21-0556","article-title":"Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor, osimertinib","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218010_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030483","article-title":"Dissection of the MKK3 functions in human cancer: a double-edged sword?","volume":"14","author":"Piastra","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.218010_bib13","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1038\/onc.2017.180","article-title":"OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc","volume":"36","author":"Ivanov","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116324","article-title":"Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer","volume":"45","author":"Yang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.canlet.2025.218010_bib15","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-17-1574","article-title":"Overcoming acquired resistance to AZD9291, A third-generation EGFR inhibitor, through modulation of MEK\/ERK-Dependent bim and Mcl-1 degradation","volume":"23","author":"Shi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218010_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172716","article-title":"DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-Mutant non-small cell lung cancer models","volume":"134","author":"Chen","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218010_bib17","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240435","article-title":"Inhibition of HTERT\/Telomerase\/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer","volume":"221","author":"Chen","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2025.218010_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218010_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105998","article-title":"The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition","volume":"175","author":"Chen","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2025.218010_bib20","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1038\/s41388-021-02057-0","article-title":"Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218010_bib21","first-page":"4931","article-title":"Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells","volume":"57","author":"Sun","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218010_bib22","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1038\/sj.onc.1202771","article-title":"Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells","volume":"18","author":"Sun","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218010_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-14-0609","article-title":"Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine","volume":"5","author":"Mender","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.218010_bib24","article-title":"Targeting Transient receptor potential Melastatin-2 (TRPM2) enhances therapeutic efficacy of third generation EGFR inhibitors against EGFR mutant lung cancer","volume":"11","author":"Chen","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2025.218010_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in Mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2025.218010_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2017.00001","article-title":"Transcriptional regulation of telomerase reverse transcriptase (TERT) by MYC","volume":"5","author":"Khattar","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2025.218010_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-022-01695-2","article-title":"Aumolertinib: a review in non-small cell lung cancer","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2025.218010_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116950","article-title":"The journey of p38 MAP kinase inhibitors: from bench to bedside in treating inflammatory diseases","volume":"280","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2025.218010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114460","article-title":"Identification of MAP Kinase Kinase 3 as a protein target of myricetin in non-small cell lung cancer cells","volume":"161","author":"Gu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2025.218010_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2018.10.016","article-title":"Gossypetin is a novel MKK3 and MKK6 inhibitor that suppresses esophageal cancer growth in vitro and in vivo","volume":"442","author":"Xie","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218010_bib31","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.2147\/OTT.S217767","article-title":"DNA methyltransferase inhibitors: catalysts for antitumour immune responses","volume":"12","author":"Dan","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2025.218010_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj1415","article-title":"Lineage-specific intolerance to oncogenic drivers restricts histological transformation","volume":"383","author":"Gardner","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218010_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2025.218010_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062152","article-title":"Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs","volume":"8","author":"Yoo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218010_bib35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cmdc.201300420","article-title":"Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation","volume":"9","author":"Rilova","year":"2014","journal-title":"ChemMedChem"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:52:41Z","timestamp":1765266761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"alternative-id":["S0304383525005804"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218010","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting MKK3\/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218010"}}